XML 40 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended
May 10, 2022
Jun. 24, 2020
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Oct. 05, 2023
Dec. 31, 2022
Jul. 08, 2021
Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax     $ 397,060 $ 879,597 $ 2,212,271 $ 2,186,577        
Deferred License Revenue, Current     176,471   176,471     $ 176,471    
Deferred License Revenue, Net of Current Portion     44,118   44,118     $ 176,471    
Alphazyme [Member]                    
Sale of Stock, Percentage of Ownership after Transaction   2.50%                
Proceeds from Sale, Maturity and Collection of Investments         1,300,000          
ID Biologics Inc [Member]                    
Investment Owned, Balance, Shares (in shares)                 129,661  
Investment Owned, Net Assets, Percentage                 0.30%  
Alphazyme [Member]                    
Ownership Percentage                   1.99%
Research and Development [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     352,942 835,480 2,079,918 1,983,636        
Inzymes Agreement APS [Member]                    
Non-refundable Upfront Payment, Received     600,000   600,000          
Revenue from Contract with Customer, Excluding Assessed Tax     67,000   67,000          
Inzymes Agreement APS [Member] | Subsequent Event [Member]                    
Non-refundable Upfront Payment, Received             $ 600,000      
A Global Food Ingredient Company [Member]                    
Collaborative Arrangement, Payment for Research and Development Agreement $ 600,000                  
Collaborative Arrangement, Duration Of Agreement (Year) 1 year                  
A Global Food Ingredient Company [Member] | Research and Development [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     0   565,000          
A Global Food Ingredient Company [Member] | Research and Development [Member] | Purchase Provision Terms [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax       339,000   452,000        
A Global Food Ingredient Company [Member] | Success Fees [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     66,000              
Janssen Pharmaceutical Companies [Member]                    
Deferred License Revenue, Current     176,000   176,000          
Deferred License Revenue, Net of Current Portion     44,118   44,118          
Deferred License Revenue     44,000   132,000          
Janssen Pharmaceutical Companies [Member] | Research and Development [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     127,000   507,000          
ID Biologics Inc [Member] | Research and Development [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     $ 0 $ 0 $ 0 $ 109,000